Evariste and University Collaboration Boosts Cancer Research
Evariste has announced an exciting partnership with the University of Southampton, aiming to create one of the most extensive transcriptomic datasets focused on oesophageal adenocarcinoma (OAC). With this innovative collaboration, they intend to pave the way for identifying groundbreaking therapeutic targets in a cancer type that presents significant treatment challenges.
Unlocking New Data
Through this partnership, Evariste plans to leverage its AI-driven discovery engine to sift through substantial amounts of data, which is clinically annotated. This endeavor will enable them to pinpoint novel therapeutic targets specifically designed for patients suffering from OAC.
Insights from Company Leaders
Anna Hercot, the CEO of Evariste, emphasized the critical role that high-quality genetic data plays in the field of precision oncology. She stated, “High quality genetic data linked to clinical outcomes is essential for identifying the next generation of precision oncology therapeutics. This data and our collaboration with the outstanding team at Southampton will help accelerate the delivery of medicines to OAC patients, who currently have very few targeted treatment options.”
Challenges in Oesophageal Cancer Treatment
Professor Tim Underwood, a renowned Consultant Surgeon, noted the current struggles in making advancements for oesophageal cancer patients, remarking, “We are really struggling to make meaningful breakthroughs for patients with oesophageal cancer, and data like this might just unlock the next generation of targets for treatment.”
Innovative Research Strategies
Dr. Zoë Walters, a key figure from the University of Southampton, shared insights on the need for innovative approaches to treatment. As she explained, “Historical strategies have focused on the perceived low hanging fruit in leveraging cancer mutations as potential therapeutic strategies. However, these have yielded very little in terms of new therapeutic strategies in the context of oesophageal cancer.” This collaboration aims to move beyond those previous constraints by utilizing their extensive dataset to uncover new targets for effective therapies.
About Evariste
Evariste stands at the intersection of technology and biotechnology, employing advanced mathematics and artificial intelligence to create small molecule therapeutics for oncology applications. Their flagship platform, Frobenius, is designed to identify promising targets and biomarkers while rapidly designing drug candidates with unmatched efficiency. The ultimate goal for Evariste is to expand the landscape of cancer treatment through innovative discoveries and improved therapeutic designs.
About University of Southampton’s School of Cancer Sciences
At the University of Southampton, researchers from the School of Cancer Sciences are spearheading groundbreaking studies aimed at deepening the understanding of cancer. This research initiative not only aims to develop more efficient treatment methods but also includes training the next generation of scientists in oncology. Together, they are committed to effecting change in treatment approaches that directly enhance patient care.
Frequently Asked Questions
What is the aim of the partnership between Evariste and the University of Southampton?
The aim is to create one of the largest transcriptomic datasets in oesophageal adenocarcinoma to identify new therapeutic targets.
Who is Anna Hercot?
Anna Hercot is the CEO of Evariste, focused on developing precision oncology therapeutics through high-quality genetic data.
What type of technology does Evariste utilize in its research?
Evariste employs artificial intelligence and advanced mathematics to develop small molecule therapeutics for oncology.
What challenges does oesophageal cancer pose for researchers?
Oesophageal cancer has proven difficult to treat, with limited therapeutic options available, making innovative research essential.
How does the University of Southampton contribute to cancer research?
The University trains future cancer researchers and conducts pioneering studies to develop more effective treatments for cancer patients.
